[A17-51] Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V
Last updated 04.01.2018
Commission awarded on 29.09.2017 by the Federal Joint Committee (G-BA).
Adult patients with locally advanced or metastatic urothelial cell carcinoma, for whom cisplatin-based chemotherapy is not suitable (first-line treatment)
Due to a lack of suitable data, added benefit versus chemotherapy specified by the physician not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.